ANALYSIS OF THE RESULTS OF FIVE YEAR PATIENTS FOLLOW-UP IN PAROXYSMAL ATRIAL FIBRILLATION TREATED WITH ANTIARRHYTHMICS
https://doi.org/10.15829/1560-4071-2018-7-67-72
Abstract
Aim. To analyze the results of 5-year follow-up of the paroxysmal atrial fibrillation patients (PAF) taking antiarrhythmic therapy (AAT)
Material and methods. Patients (n=500) were selected to 11 groups: I — healthy, II — controls, III-XI — PAF taking AAT. The baseline parameters of heart rate variability (HRV) were assessed during 5-year follow-up.
Results. Decrease of SDNN does 1,9 times increase the risk of AF development during the first 3 months from preventive AAT start. Decrease of RMSSD does 3,9 times increase the risk of AF during the first 2 weeks, and 1,9 times — 3 months; decrease of Delta X increases the risk of AF 3,9 times during 2 weeks, 2 times — during 3 months, 1,4 times — during 6 months, 1,3 times — during 12 months and 3 years. Increase of Amo does 1,8 times increase the risk of AF during first 3 months. If there was baseline decrease of Delta X and RMSSD, then within 2 weeks the AF paroxysm developed in 7,9% patients, and in 3 months — 15,9% patients. With the decrease of Delta X and RMSSD, in combination with low SDNN, the probability of sinus rhythm retention during 1 year is 51,2%.
Conclusion. PAF patients taking preventive AAT demand for ECG assessment of HRV parameters no less than once per 3 months.
About the Authors
T. A. RybakovaRussian Federation
Saransk
V. V. Stolyarova
Russian Federation
Saransk
Competing Interests: ФГБОУ ВО "Национальный исследовательский Мордовский государственный университет им. Н.П. Огарева"
M. G. Nazarkina
Russian Federation
Saransk
N. Yu. Leschankina
Russian Federation
Saransk
References
1. Ardashev AV, Shlyakhto EV, Arutyunov GP, Belenkov YN. National recommendations on risk identification and prevention of sudden cardiac death. Clinical practice. 2012;3;4:1-77. (In Russ.)
2. Boytsov SA, Nikulin NN, Yakushin SS, et al. Sudden cardiac death in patients with ischemic heart disease: prevalence, detection and problems of statistics. Russ J Cardiol. 2011;16(2):59-64. (In Russ.)
3. Shlyakhto EV. Cardio-vascular diseases in 21th century: new challenges and new solutions. Annals of the Russian academy of medical sciences. 2012;67(5):13. (In Russ.)
4. Erlikh AD. A study of the evidence base for using lappaconitine hydrobromide in patients with atrial fibrillation. Cardiology. 2016;3:48-53. (In Russ.)
5. Shenesa M, Camm AJ. Management of atrial fibrillation. A practical approach Oxford: University Press. 2015. p. 150. ISBN 978-0-19-968631-5.
6. Kanorsky SG, Kovalenko YuS. Modern pharmacotherapy of atrial fibrillation. Russ J Cardiol. 2017;22(7):171-7. (In Russ.)
7. Ryabykina GV, Sobolev AV. Holter and bifunctional monitoring ECG and blood pressure. — Moscow: publishing house “MEDPRAKTIKA-M”, 2010. p. 320. (In Russ.) Рябыкина Г. В., Соболев А. В. Холтеровское и бифункциональное мониторирование ЭКГ и артериального давления. М.: ИД “МЕДПРАКТИКА-М”, 2010.c. 320. ISBN: 978-5-98803-227-4.
8. Weinschenk SW, Beise RD, Lorenz J. Heart rate variability (HRV) in deep breathing tests and 5-min short-term recordings: agreement of ear photoplethysmography with ECG measurements, in 343 subjects. Eur. J Appl Physiol. 2016;116(8):1527-35. doi:10.1007/s00421-016-3401-3.
9. Draghici AE, Taylor J. The physiological basis and measurement of heart rate variability in humans. J Physiol Anthropol. 2016;35(1):22. doi:10.1186/s40101-016-0113-7.
10. Revishvili ASh, Narda GSh, Rzaev FG, et al. Electrophysiological and clinical predictors of radiochastotnyi pulmonary veins and left atrium in patients with persistent form of atrial fibrillation. Annals of Arrhythmology. 2014;11(1):46-53. (In Russ
11. Kanorsky SG. Antiarrhythmic therapy in patients with paroxysmal and persistent forms of atrial fibrillation: determination of achievable goal and evaluation of available funds. Cardiology. 2014;2:70-4. (In Russ.)
Review
For citations:
Rybakova T.A., Stolyarova V.V., Nazarkina M.G., Leschankina N.Yu. ANALYSIS OF THE RESULTS OF FIVE YEAR PATIENTS FOLLOW-UP IN PAROXYSMAL ATRIAL FIBRILLATION TREATED WITH ANTIARRHYTHMICS. Russian Journal of Cardiology. 2018;(7):67-72. (In Russ.) https://doi.org/10.15829/1560-4071-2018-7-67-72